- Home
- INCY vs LECO Comparison
INCY vs LECO Comparison
Compare INCY & LECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- LECO
- Stock Information
- Founded
- INCY 1991
- LECO 1895
- Country
- INCY United States
- LECO United States
- Employees
- INCY N/A
- LECO N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- LECO Industrial Machinery/Components
- Sector
- INCY Health Care
- LECO Industrials
- Exchange
- INCY Nasdaq
- LECO Nasdaq
- Market Cap
- INCY 17.0B
- LECO 12.5B
- IPO Year
- INCY 1993
- LECO N/A
- Fundamental
- Price
- INCY $108.01
- LECO $228.57
- Analyst Decision
- INCY Buy
- LECO Buy
- Analyst Count
- INCY 19
- LECO 9
- Target Price
- INCY $89.19
- LECO $244.00
- AVG Volume (30 Days)
- INCY 2.8M
- LECO 343.8K
- Earning Date
- INCY 10-28-2025
- LECO 10-30-2025
- Dividend Yield
- INCY N/A
- LECO 1.39%
- EPS Growth
- INCY 3878.02
- LECO 11.30
- EPS
- INCY 5.90
- LECO 9.34
- Revenue
- INCY $4,813,105,000.00
- LECO $4,176,319,000.00
- Revenue This Year
- INCY $19.33
- LECO $7.79
- Revenue Next Year
- INCY $10.47
- LECO $5.86
- P/E Ratio
- INCY $17.95
- LECO $24.36
- Revenue Growth
- INCY 18.09
- LECO 3.24
- 52 Week Low
- INCY $53.56
- LECO $161.11
- 52 Week High
- INCY $108.81
- LECO $249.19
- Technical
- Relative Strength Index (RSI)
- INCY 83.12
- LECO 42.24
- Support Level
- INCY $91.16
- LECO $224.47
- Resistance Level
- INCY $108.81
- LECO $230.14
- Average True Range (ATR)
- INCY 4.46
- LECO 6.14
- MACD
- INCY 1.41
- LECO -1.05
- Stochastic Oscillator
- INCY 96.57
- LECO 33.39
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About LECO Lincoln Electric Holdings Inc.
Lincoln Electric is a leading manufacturer of welding, cutting, and brazing products. Its portfolio includes arc-welding solutions, plasma and oxy-fuel cutting systems, brazing and soldering alloys, and automation solutions. Lincoln Electric serves clients across general fabrication, heavy industries, automotive, construction, shipbuilding, energy, and process industries, among others. Based in Cleveland, Lincoln Electric operates in 19 countries and employs 11,000 worldwide. The company generated roughly $4 billion in sales in 2024.